Back
 JCT  Vol.5 No.13 , November 2014
Tumor Response to Temsirolimus for Epithelioid Angiomyolipoma and Novel Mutation of SMARCB1/INI1 Tumor Suppressor Gene
Jung Yong Hong1, Jeeyun Lee2*, Kyoung-Mee Kim3, Sung Joo Kim4*
Show more
Abstract: Epithelioid angiomyolipoma (EAML) is a rare morphologic variant of classic angiomyolipoma (AML), showing potentially malignant phenotype. AML is a benign mesenchymal tumor, which shows frequent inactivating mutations of TSC1 (encodes harmartin) or TSC2 (encodes tuberin) genes. Disruption of harmatin-tuberin complex and subsequent inappropriate activation of mTOR pathway is a distinct feature of AML. Thus, mTOR pathway inhibitors have shown significant clinical response in AML. Compared to the great success of mTOR inhibitors in AML, there is no standard therapy for EAML yet. Here, we present a patient with EAML who responded well to mTOR inhibitor (temsirolimus) but suffered rapid disease progression after cessation of temsirolimus. In addition, we performed Cancer Hotspot Panel (Ion AmpliSeqTM) analysis to identify novel tumorigenic properties of EAML. Of note, Cancer Hotspot Panel analysis revealed novel missense mutation in SMARCB1 (c.1119-41G > A) tumor suppressor gene and subsequent immunohistochemistry analysis also revealed weak and partial losses ofSMARCB1/INI1 protein in nuclei of tumor cells. In this study, we suggest that mTOR inhibitors also can be effective against EAML. However, the long-term efficacy of mTOR inhibitors in EAML needs to be supported in further studies. Furthermore, we speculate that the newly found missense mutation ofSMARCB1/INI1 gene can be the possible novel tumorigenic properties of EAML and highlights the possibility of further novel targeted therapy beyond mTOR inhibitors in EAML.
Keywords: Epithelioid Angiomyolipoma, Temsirolimus, SMARCB1/INI1
Cite this paper: Hong, J. , Lee, J. , Kim, K. and Kim, S. (2014) Tumor Response to Temsirolimus for Epithelioid Angiomyolipoma and Novel Mutation of SMARCB1/INI1 Tumor Suppressor Gene. Journal of Cancer Therapy, 5, 1215-1222. doi: 10.4236/jct.2014.513123.
References

[1]   Curatolo, P., Bombardieri, R. and Jozwiak, S. (2008) Tuberous Sclerosis. Lancet, 372, 657-668. http://dx.doi.org/10.1016/S0140-6736(08)61279-9

[2]   Crino, P.B., Nathanson, K.L. and Henske, E.P. (2006) The Tuberous Sclerosis Complex. The New England Journal of Medicine, 355, 1345-1356. http://dx.doi.org/10.1056/NEJMra055323

[3]   Dibble, C.C. and Manning, B.D. (2013) Signal Integration by mTORC1 Coordinates Nutrient Input with Biosynthetic Output. Nature Cell Biology, 15, 555-564. http://dx.doi.org/10.1038/ncb2763

[4]   Huang, J. and Manning, B.D. (2008) The TSC1-TSC2 Complex: A Molecular Switchboard Controlling Cell Growth. The Biochemical Journal, 412, 179-190. http://dx.doi.org/10.1042/BJ20080281

[5]   Huang, J., Dibble, C.C., Matsuzaki, M. and Manning, B.D. (2008) The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2. Molecular and Cellular Biology, 28, 4104-4015.
http://dx.doi.org/10.1128/MCB.00289-08

[6]   El-Hashemite, N., Zhang, H., Henske, E.P. and Kwiatkowski, D.J. (2003) Mutation in TSC2 and Activation of Mammalian Target of Rapamycin Signalling Pathway in Renal Angiomyolipoma. Lancet, 361, 1348-1349. http://dx.doi.org/10.1016/S0140-6736(03)13044-9

[7]   Kenerson, H., Folpe, A.L., Takayama, T.K. and Yeung, R.S. (2007) Activation of the mTOR Pathway in Sporadic Angiomyolipomas and Other Perivascular Epithelioid Cell Neoplasms. Human Pathology, 38, 1361-1371. http://dx.doi.org/10.1016/j.humpath.2007.01.028

[8]   Bissler, J.J., Kingswood, J.C., Radzikowska, E., Zonnenberg, B.A., Frost, M., Belousova, E., et al. (2013) Everolimus for Angiomyolipoma Associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis (EXIST-2): A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial. Lancet, 381, 817-824. http://dx.doi.org/10.1016/S0140-6736(12)61767-X

[9]   Bissler, J.J., McCormack, F.X., Young, L.R., Elwing, J.M., Chuck, G., Leonard, J.M., et al. (2008) Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis. The New England Journal of Medicine, 358, 140-151. http://dx.doi.org/10.1056/NEJMoa063564

[10]   Cibas, E.S., Goss, G.A., Kulke, M.H., Demetri, G.D. and Fletcher, C.D. (2001) Malignant Epithelioid Angiomyolipoma (“Sarcoma ex Angiomyolipoma”) of the Kidney: A Case Report and Review of the Literature. The American Journal of Surgical Pathology, 25, 121-126.
http://dx.doi.org/10.1097/00000478-200101000-00014

[11]   Brimo, F., Robinson, B., Guo, C., Zhou, M., Latour, M. and Epstein, J.I. (2010) Renal Epithelioid Angiomyolipoma with Atypia: A Series of 40 Cases with Emphasis on Clinicopathologic Prognostic Indicators of Malignancy. The American Journal of Surgical Pathology, 34, 715-722.

[12]   Nese, N., Martignoni, G., Fletcher, C.D., Gupta, R., Pan, C.C., Kim, H., et al. (2011) Pure Epithelioid PEComas (So-Called Epithelioid Angiomyolipoma) of the Kidney: A Clinicopathologic Study of 41 Cases: Detailed Assessment of Morphology and Risk Stratification. The American Journal of Surgical Pathology, 35, 161-176. http://dx.doi.org/10.1097/PAS.0b013e318206f2a9

[13]   Wolff, N., Kabbani, W., Bradley, T., Raj, G., Watumull, L. and Brugarolas, J. (2010) Sirolimus and Temsirolimus for Epithelioid Angiomyolipoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28, e65-e68. http://dx.doi.org/10.1200/JCO.2009.26.3061

[14]   Wagner, A.J., Malinowska-Kolodziej, I., Morgan, J.A., Qin, W., Fletcher, C.D., Vena, N., et al. (2010) Clinical Activity of mTOR Inhibition with Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28, 835-840.
http://dx.doi.org/10.1200/JCO.2009.25.2981

[15]   Shitara, K., Yatabe, Y., Mizota, A., Sano, T., Nimura, Y. and Muro, K. (2011) Dramatic Tumor Response to Everolimus for Malignant Epithelioid Angiomyolipoma. Japanese Journal of Clinical Oncology, 41, 814-816. http://dx.doi.org/10.1093/jjco/hyr035

[16]   Higa, F., Uchihara, T., Haranaga, S., Yara, S., Tateyama, M., Oshiro, Y., et al. (2009) Malignant Epithelioid Angiomyolipoma in the Kidney and Liver of a Patient with Pulmonary Lymphangioleiomyomatosis: Lack of Response to Sirolimus. Internal Medicine, 48, 1821-1825.
http://dx.doi.org/10.2169/internalmedicine.48.2411

[17]   Subbiah, V., Trent, J.C. and Kurzrock, R. (2010) Resistance to Mammalian Target of Rapamycin Inhibitor Therapy in Perivascular Epithelioid Cell Tumors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28, e415. http://dx.doi.org/10.1200/JCO.2010.29.4678

[18]   Vries, R.G., Bezrookove, V., Zuijderduijn, L.M., Kia, S.K., Houweling, A., Oruetxebarria, I., Raap, A.K. and Verrijzer, C.P. (2005) Cancer-Associated Mutations in Chromatin Remodeler hSNF5 Promote Chromosomal Instability by Compromising the Mitotic Checkpoint. Genes & Development, 19, 665-670. http://dx.doi.org/10.1101/gad.335805

[19]   Jackson, E.M., Sievert, A.J., Gai, X., Hakonarson, H., Judkins, A.R., Tooke, L., et al. (2009) Genomic Analysis Using High-Density Single Nucleotide Polymorphism-Based Oligonucleotide Arrays and Multiplex Ligation-Dependent Probe Amplification Provides a Comprehensive Analysis of INI1/SMARCB1 in Malignant Rhabdoid Tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 15, 1923-1930.
http://dx.doi.org/10.1158/1078-0432.CCR-08-2091

[20]   Kohashi, K., Oda, Y., Yamamoto, H., Tamiya, S., Izumi, T., Ohta, S., Taguchi, T., Suita, S. and Tsuneyoshi, M. (2007) Highly Aggressive Behavior of Malignant Rhabdoid Tumor: A Special Reference to SMARCB1/INI1 Gene Alterations Using Molecular Genetic Analysis including Quantitative Real-Time PCR. Journal of Cancer Research and Clinical Oncology, 133, 817-824.
http://dx.doi.org/10.1007/s00432-007-0223-z

[21]   Kohashi, K., Oda, Y., Yamamoto, H., Tamiya, S., Oshiro, Y., Izumi, T., Taguchi, T. and Tsuneyoshi, M. (2008) SMARCB1/INI1 Protein Expression in Round Cell Soft Tissue Sarcomas Associated with Chromosomal Translocations Involving EWS: A Special Reference to SMARCB1/INI1 Negative Variant Extraskeletal Myxoid Chondrosarcoma. The American Journal of Surgical Pathology, 32, 1168-1174. http://dx.doi.org/10.1097/PAS.0b013e318161781a

[22]   Kohashi, K., Oda, Y., Yamamoto, H., Tamiya, S., Matono, H., Iwamoto, Y., Taguchi, T. and Tsuneyoshi, M. (2010) Reduced Expression of SMARCB1/INI1 Protein in Synovial Sarcoma. Modern Pathology, 23, 981-990. http://dx.doi.org/10.1038/modpathol.2010.71

[23]   Brenca, M., Rossi, S., Lorenzetto, E., Piccinin, E., Piccinin, S., Rossi, F.M., et al. (2013) SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ. Molecular Cancer Therapeutics, 12, 1060-1072. http://dx.doi.org/10.1158/1535-7163.MCT-13-0005

[24]   Kohashi, K., Izumi, T., Oda, Y., Yamamoto, H., Tamiya, S., Taguchi, T., et al. (2009) Infrequent SMARCB1/INI1 Gene Alteration in Epithelioid Sarcoma: A Useful Tool in Distinguishing Epithelioid Sarcoma from Malignant Rhabdoid Tumor. Human Pathology, 40, 349-355.
http://dx.doi.org/10.1016/j.humpath.2008.08.007

[25]   Imbalzano, A.N. and Jones, S.N. (2005) Snf5 Tumor Suppressor Couples Chromatin Remodeling, Checkpoint Control, and Chromosomal Stability. Cancer Cell, 7, 294-295.
http://dx.doi.org/10.1016/j.ccr.2005.04.001

[26]   Alarcon-Vargas, D., Zhang, Z., Agarwal, B., Challagulla, K., Mani, S. and Kalpana, G.V. (2006) Targeting Cyclin D1, a Downstream Effector of INI1/hSNF5, in Rhabdoid Tumors. Oncogene, 25, 722-734. http://dx.doi.org/10.1038/sj.onc.1209112

[27]   Smith, M.E., Cimica, V., Chinni, S., Challagulla, K., Mani, S. and Kalpana, G.V. (2008) Rhabdoid Tumor Growth Is Inhibited by Flavopiridol. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 14, 523-532. http://dx.doi.org/10.1158/1078-0432.CCR-07-1347

 
 
Top